Unicycive’s Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden Benzinga Digital Content Studio

Digital Asset Direct by Unicycive Therapeautics, Inc.

Detroit, MI | November 08, 2022 09:00 AM Eastern Standard Time

NASDAQ: UNCY Unicycive’s Doug Jermasek, EVP-Corporate Development discusses the importance of medication compliance and the issues with pill burden in this interview with Benzinga. Unicycive Therapeutics is a cutting edge biotechnology company developing potentially breakthrough therapies for patients with kidney disease. Visit them at www.unicycive.com to learn more!

Contact Details

Anne Marie Fields - Stern Investor Relations

+1 212-362-1200

annemarie.fields@sternir.com

Company Website

https://unicycive.com/